Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada.

ABSTRACT:

Background

In the phase iii palette trial of pazopanib compared with placebo in patients with advanced or metastatic soft-tissue sarcoma (sts) who had received prior chemotherapy, pazopanib treatment was associated with improved progression-free survival (pfs). We used an economic model and data from palette and other sources to evaluate the cost-effectiveness of pazopanib in patients with advanced sts who had already received chemotherapy.

Methods

We developed a multistate model to estimate expected pfs, overall survival (os), lifetime sts treatment costs, and quality-adjusted life-years (qalys) for patients receiving pazopanib or placebo as second-line therapy for advanced sts. Cost-effectiveness was calculated alternatively from the health care system and societal perspec

SUBMITTER: Delea TE 

PROVIDER: S-EPMC4257119 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature